

Global Equity Strategy

US election implications

Investment Strategy | Strategy

Big picture on markets: We remain constructive on equities. In our view, central banks will continue to suppress government & corporate bonds, hence the need to focus on the ERP; the change in attitude to fiscal policy and the vaccine are all much more important than the US election result.

The key issue for markets is the near-term fiscal boost: On our estimates: c\$2trn under a Democratic clean sweep, \$1trn under a Trump Presidency, and \$500bn under a Biden Presidency and Republican Senate (but this could be higher). The long-term fiscal stimulus (c\$2trn infrastructure) will probably be half the amount without a Biden sweep. Under a Biden Presidency and Republican Senate scenario, we expect GDP growth to be at least 50bp lower than under a Trump Presidency (and at least 1.5% lower than under a Biden clean sweep).

The market is right to be relatively sanguine. The negative impact of Democrat policies (on tax, regulation and min wages) is offset to a large extent by the positive impacts (on GDP growth, easier trade relations). We see a marginal Democratic clean sweep boosting EPS by 3%, a Trump presidency leaving EPS up 2%, and a Biden Presidency with Republican Senate resulting in a 3% hit to EPS. A split legislature should mean less regulation that helps 30% of the US market (tech ex-semis, and pharma) and the fall in bond yields underpins the equity risk premium (7.4% against a warranted level of 4.8%).

Non-US equities no major implication. Non-US equities are more highly operationally leveraged; but a Biden presidency eases trade tensions (Biden wanted to normalize relations with the EU and has been less aggressive with China). A Biden win should see NJA outperform.

Sectors: Banks and materials have been the most correlated sectors with Biden's popularity (tech and healthcare the worst). **Don't give up on cyclical:** We are benchmark European cyclical which are discounting a PMI of just 52 (1.2% GDP). We are likely close to a vaccine and in general governments are committed to spending if GDP disappoints. We had today an unwind of the cyclical rally of the last 2 weeks.

Some areas of common ground between Biden and Trump: Repealing Section 230 of the Communications Decency Act (for platform companies), bringing drug prices down to international levels, and more infrastructure spending. However, there is limited Republican Senate support for drug price control and infrastructure. Executive orders can achieve a lot in terms of trade and Biden wants to use them for procurement.

Specific areas: Biden victory is negative for oil; whilst Trump is good for defence (P/E relatives at 20-year lows). A clean sweep would be very supportive for construction materials (especially insulation) and renewables; negative for oil, luxury, drugs and platform companies.

A second lockdown? We don't think President Biden would impose a lockdown (not least because it is up to the mayors and governors, Trump is in charge until Jan 20th and only 37% of the public supports significantly stricter measures).

Contested election: As in 2000, we think the Supreme Court would probably not allow this to go on past 8 December. *NB this is up to date as of 17.45 GMT/12.45 ET.*

Research Analysts

Andrew Garthwaite

44 20 7883 6477
andrew.garthwaite@credit-suisse.com

Robert Griffiths

44 20 7883 8885
robert.griffiths@credit-suisse.com

Nicolas Wylenzek

44 20 7883 6480
nicolas.wylenzek@credit-suisse.com

Mengyuan Yuan

44 20 7888 0368
mengyuan.yuan@credit-suisse.com

Asim Ali

44 20 7883 2480
asim.ali@credit-suisse.com

Timothy O'Sullivan

44 20 7888 9803
timothy.osullivan@credit-suisse.com

DISCLOSURE APPENDIX AT THE BACK OF THIS REPORT CONTAINS IMPORTANT DISCLOSURES, ANALYST CERTIFICATIONS, LEGAL ENTITY DISCLOSURE AND THE STATUS OF NON-US ANALYSTS. US Disclosure: Credit Suisse does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

US election

Biden win most likely but clean sweep has a low probability.

The US Presidential election remains highly uncertain. Joe Biden maintains a credible path to victory were he to win Wisconsin, Michigan and Nevada, but vote counts, and legal challenges, could still take some days. Nonetheless, given the information we have (particularly with respect to the Senate), we would make the following tentative conclusions: we believe there is a 70% chance of a Biden Presidency, a 20% of a Trump Presidency and a 10% chance of a Democratic clean sweep, though the result may not be decisively known until Nevada releases its next count on Thursday or until Pennsylvania has finished its count on Friday. If the Senate result comes down to Georgia, then we will not know the result until the runoff on 5 January.

How much of a fiscal boost will be delivered?

The size of any near term fiscal boost is the key to markets, and in particular the following three areas: Federal unemployment benefit (bearing in mind that the FEMA lost wage assistance are running out very quickly), aid to states (which are in deficit and by law have to have a balance budget which could drive significant spending cuts) and the renewal of the PayCheck Protection Programme.

The near-term fiscal spending outcomes going into this election ranged from the \$2.2trn proposed by Nancy Pelosi down to \$500bn proposed by Senate Republicans. In our judgement, a Trump White House win with a split Congress would likely lead to a stimulus outcome somewhere in the middle of this range (around \$1trn, itself down from the \$1.8trn Trump had earlier sought). A Biden White House win with Republican Senate would, we believe, see the stimulus package toward the lower end of this range, which in turn would obviously limit any GDP growth upside (a clean Democratic sweep could have seen growth forecasts rise by 1.5p.p.). That said, in July, the Republican Senators did sign up to a \$1trn fiscal plan, so perhaps there is scope for their current \$500bn offering to increase in size.

Critically we have consistently seen that US politicians react to stock market or economic weakness by easing fiscal policy.

Clearly, there is a lot of uncertainty over this. There are 4 Republican Senators up for reelection in 2022 (and 7 in total) in potentially very close races and it is possible that one of these could be persuaded to vote with the Democrats in return for more fiscal spending in his own state. Trump on his campaign trail suggested more fiscal easing than he did in his manifesto (admittedly via tax cuts rather than spending).

The long-term fiscal boost is less relevant than the short-term fiscal boost. Under a Biden clean sweep, there was \$2trn of largely green related infrastructure (as well as \$775bn on making childcare and nursing more affordable and \$700bn on Made in America government procurement and R&D of which some is counted in the infrastructure spending) yet Moody's estimate that the tax hikes would be just \$1.4trn (and with 80% of the tax hikes falling on the richest 1% of the population, who have a low marginal propensity to consume). Hence, we estimate that a Democratic clean sweep, though unlikely, would lead to a long-term fiscal boost of an additional 1% p.a. quite easily.

Under a Biden split, we could see \$500bn of infrastructure spending; under a Trump split, there may be similar increase in infrastructure spending.

Markets

For the most part, net net little change to EPS....

The absence of a sweep outcome brings positives and negatives: in most of our EPS scenarios, we had the negative impact of a Democrat policy platform (on tax, regulation and minimum wages) being offset to a large extent by their positive spending impact (on GDP growth, and easier trade relations).

Figure 1: Impact on EPS

Likely size of corona stimulus					
Biden marginal clean sweep		Biden + Republican senate		Trump + Democratic house	
Proposal	% of GDP*	Proposal	% of GDP*	Proposal	% of GDP*
Corona stimulus	\$1.5tn fiscal stimulus 4.0%	\$500bn fiscal stimulus 2.0%		\$1tn fiscal stimulus 3.5%	
* adjusted for clear water impact					
EPS impact					
Outcome	EPS impact	Outcome	EPS impact	Outcome	EPS impact
Corporate tax increase	Probability high -5.4%	No tax increase	0%	No tax increase	0.0%
Other tax increases	Probability low 0.0%				
Minimum wage legislation	Probability low 0.0%	No min. wage increase	0%	No min. wage increase	0.0%
EPS impact from tax reform and minimum wage increase			0.0%		0.0%
EPS impact from fiscal stimulus Large fiscal stimulus		Small fiscal drag	-3%	Small fiscal stimulus	2.0%
EPS impact (adj. for fiscal stimulus)			-3.0%		2.0%

Source: Credit Suisse research

We can see that:

- A Biden Presidency but Republican Senate reduces EPS by c3%,
- A Trump presidency with split Congress increases EPS by c2%
- A Clean sweep increases EPS by 3%.


To some extent, these earnings numbers underestimate the benefit of stalemate and compromise. It will be much harder to regulate technology (recall the Republicans refusing the highly critical Congressional Report into the Big 4) or pass healthcare reform. Close to 30% of the US market cap is pharma and tech (ex-semis) which would be under less regulatory attack under a split Congress than a Democrat clean sweep. Moreover, growth stocks (c44% of US market cap) benefit from a lower discount rate (i.e. lower bond yield).

Bigger picture what matters more for markets:


We would argue that there are three critical issues in markets that are, if anything, more important than the US election result:

- 1) The vaccine (which in turns allow normalization). We would expect a successful announcement on a Phase 3 trial by year end and incremental roll out of c1bn a quarter. Even 50% efficacy is enough to smooth the curve.
- 2) Globally politicians are committed to fiscal QE; any weakness in GDP leads to a fiscal response.
- 3) The suppression of bond and corporate bond yields.

Central banks still have significant fire power and are keeping both bond yields and corporate bond yields abnormally low. This impact is illustrated in the disconnect between ISM and the 10 year bond yield. This means investors not only have to focus on the equity risk premium (currently the ERP is 7.4% on our numbers against our models that suggest that, even if ISM falls to 55 and credit spreads go to average levels, then equities (S&P 500) should be close to 4,020 by the end of next year) but we are starting to see a bond for equity switch (as bonds no longer diversify). Less than 10% of the Fed schemes have been used (and just 7% of the Main Street Lending Programmes have been allocated).

Figure 2: US ERP is well above warranted levels


Source: Refinitiv, Credit Suisse research

Figure 3: The 10y has significantly disconnected from ISM


Source: Refinitiv, Credit Suisse research

Regions

In our view, the less the fiscal stimulus in the US, the worse it is for the more operationally leveraged global markets. Moreover, non-US markets have a lower proportion of market cap in healthcare and technology ex semis (the relative winners from lighter regulatory backdrop).

Figure 4: US has low operational leverage


Source: Refinitiv, Credit Suisse research

Figure 5: Financials and materials sector weight minus tech (ex-semis) and pharma

Source: Refinitiv, Credit Suisse research

Trade relations remain up to the President who can rule via executive action. As we highlighted in our note on Monday (see [US election scenarios](#), 02 Nov), Biden tends to be a multilateralism and has spoken about wanting to normalize relations with Europe.

We can see that Biden has been perceived to be good for non-US relative to US equities.

Figure 6: Biden has been perceived to be relatively better for non-US equities


Source: Refinitiv, Credit Suisse research

Bond yields

Volatility in the bond market has picked up. 10 year yields have risen sharply from 68bp Oct 15 to peak overnight today at 94bp and is now 78bp. We think that the Fed would not allow the 10 year bond yield to rise much above the 1.25% to 1.5% range (bearing in mind that average maturity of mortgage debt and corporate bond debt is close to 11 year and 7 years respectively); thus, we would expect any large rise in bond yields would be met by some form of yield curve control. We can see a record disconnect between ISM, highlighting the impact of central bank buying.

Sectors

Clearly the sectors most correlated with Biden had been materials and banks and those with Trump are pharma and tech (ex-semis).

Figure 7: US sector correlation with Trump popularity YTD

Source: Bloomberg Finance L.P., Refinitiv, Credit Suisse research

We have only seen an unwind of the 2 week cyclical trade today.

Figure 8: Recent US sector performance- an unwind today of the past two weeks cyclical trade

US Sectors	1 mth rel performance	2 wk rel performance	1 wk rel performance	Intraday rel. performance
Small vs Large	1.94%	1.56%	1.98%	-2.19%
Banks rel market	-1.39%	4.05%	5.26%	-5.45%
Tech rel market	0.95%	-1.72%	-1.29%	1.35%
Pharma rel market	-1.61%	-1.32%	-0.79%	2.15%
Industrials rel Market	-0.02%	4.04%	1.15%	-2.65%


*intraday prices last refreshed at 10.45am US Eastern Time

Source: Refinitiv, Credit Suisse research

Don't give up on the cyclical trade

We are benchmark European cyclical but would not give up on the cyclical trade as:

- Cyclical are pricing in a PMI of 52 (1.3% GDP growth) against a backdrop when the underlying resilience in the US economy was much stronger than expected (e.g. ISM new orders on Monday was in the top 1% of its range) as is China.

Figure 9: The cyclicals-to-defensives ratio is discounting PMIs at c52

Source: Refinitiv, Markit, Credit Suisse research

- We are closer to a vaccine. Around the turn of the year, we should have the result of three Phase 3 trials
- It is too early to say there is clear cut gridlock in the Senate.

The policy outlook

What can the President do by executive action?


Essentially the President is in charge of trade policy (as Donald Trump has shown) and Biden has said he would use executive orders to increase government procurement (Biden has pledged to sign six 'Buy American' executive orders during his first week in office and has pledged \$400bn on 'Made in America' government procurement, and \$300bn in R&D on US technology). Biden might be able to use executive actions to impose some requirements for cleaner energy and maybe on areas of tech but this would be harder and subject to legal challenges.

What are areas of agreement between Biden and Trump?

Plausibly, there could be some common ground found in sustainability related areas of infrastructure spending and regulation of technology (e.g. the repeal/amendment of Section 230 of the Communications Decency Act). However, even here the common ground seems limited (the recent House Judiciary Committee report on monopoly power in tech was endorsed only by the Democrat members of the Committee despite increasing disquiet from Republicans at the power of the big tech firms).

Trump has favoured infrastructure but has not delivered anything so far (but clearly his infrastructure focus would not be green related). Hence, the infrastructure front, we would be surprised to see a package of more than \$500bn over the next five years.

Donald Trump wanted to lower drug prices to international levels via his most favored nations (MFN) approach, which he would establish via an executive order. Despite Trump's aggressive rhetoric, he has had relatively few successes in this arena. Biden also wants to reduce drug prices to global levels and, in the absence of a majority in Congress, could choose a similar approach to Trump. We believe investors should be underweight big cap pharma (see [Utilities to overweight, pharma and energy to underweight](#), 4 Aug).

Figure 10: ...which would be consistent with c1.2% GDP growth

Source: Refinitiv, Markit, Credit Suisse research

Sector performance under Biden and split Congress

Under a Biden presidency, independent of Congress, oil is likely to suffer. We expect Biden to try to improve relations with Iran, which could lead to the potential release 2m bpd of oil into the market, and ban drilling on Federal Land.


Moreover, Biden would likely show goodwill to Europe by abolishing the \$7.5bn punitive tariff imposed by Trump (to the benefit of spirit, champagne and aerospace companies).

The Senate remains a key actor when it comes to the appointment and approval of many key positions across the judiciary and wider government. Having a Senate controlled by a different party to the executive could make any such appointments drawn out, and could act as a lightning rod for broader political division in the country. Moreover, it would limit the chances of major regulatory reform.

Sector performance if Trump becomes President?


This is likely to lead to a relief rally in those areas that would have faced higher regulation (tech and pharma). Defense companies should also do well with Trump keeping up pressure on NATO members to spend more. This is at a time when US defense stocks are trading on P/E relatives at 30 year lows and European defense stocks look cheap relative to US stocks.

Figure 11: US defence stocks have de-rated sharply



Source: Refinitiv, Credit Suisse research

Figure 12: European defence stocks trade below their average relative to their US peers on 12m forward P/E...



Source: Refinitiv, Credit Suisse research

We think a lockdown under a Biden Presidency is unlikely

One of the concerns is whether Biden would implement a national lockdown to control COVID. The reality is that President Trump will remain in power until 20 January and, by that stage if there is a continuing sharp rise in infections, it would likely be too late to implement a lockdown. Moreover, the lockdowns are implemented by state governors rather than the President and so far few have hinted that they are prepared for such a move. In this, they are largely reflecting public opinion, with only 37% of Americans supporting significantly stricter measures (proxied by school closure), down from 76% in April, according to YouGov. Of course, state governors (11 governorships are up in 2020) might change their minds after their election. Finally, Biden's policy website only mentions testing and masks as central to combatting COVID, with no mention of federal lockdowns.

What about a clean sweep for Biden?


While looking increasingly unlikely, Biden could still achieve a small majority in the Senate (50) and this means that compromise would be required. This could see a lot of legislation around his green agenda being implemented.

The areas of uncertainty are: i) whether Biden would still try to abolish the filibuster rule and ii) whether he would try to pack the Supreme Court (given Democrat concerns that the current court threatens to overturn *Roe v. Wade* and the ACA).

Under this outcome we believe the clear winners would be renewables (Biden wants zero carbon emission from power generation by 2035) and insulation plays (see [US election outlook](#), 2 Oct).

Negatively-impacted sectors under a Biden clean sweep would be luxury (the top 1% pay 80% of the tax hike), oil (owing to the move to renewables and EV) and tech (with the platform companies facing higher regulation/taxation) and pharma. We find that, when there has been a clean sweep and an attack on pharma, that sector remains on a 10% to 20% discount to the market for up to 20 months (compared to a 2% premium if we look at normalized earnings).

Figure 13: The pharma sector is very sensitive to political risk and stays cheap for a long time in the face of meaningful healthcare reform (it is not cheap if we adjust for trend earnings for the overall market)



Source: Refinitiv, Credit Suisse research

Figure 14: Historically, it stays cheap for 10 to 20 months after the implementation of meaningful healthcare reform

Start of derating	Start of rerating	Magnitude of derating, % change in rel PE	Length of time (in mth)
Nov-92	Jul-94	-31%	20
Dec-08	Oct-09	-43%	10
Start of current derating		Magnitude of current derating	
Apr-20		-30%	

Source: Refinitiv, Credit Suisse research

Appendix

Figure 15: Scenario summary

		Biden marginal clean sweep	Biden + Republican Senate	Trump + Democratic House
Government bond yields		+10bps	-20bps	-5bps
DXY		-0.5%	-0.5%	1.0%
EPS impact	Tax reform/min wages	-5.4%	0%	0%
	Adj. for fiscal stimulus	2.6%	-3.0%	2.0%
Market implications		US and Non US equities rise modestly and EM outperform (best outcome for equities as an asset class)	US and NJA outperform	Positive for US equities and EM underperforms
Style implications		Value outperforms	Growth outperforms	Growth outperforms
Sector winners		Construction, infrastructure, ESG, financials	Healthcare and tech	Secular growth: tech, energy
Sector losers		Healthcare, energy, tech, luxury	Energy, value cyclicality	Value cyclicality: banks, autos
Key policy conclusions		\$2trn infrastructure investment over 4 years. Higher corporate tax rate - 28% from 21% Rejoin Paris Climate Accord; net zero emissions by 2050 Increased regulation of tech Limit drug price rises; strengthen public health option A more conciliatory approach to trade with allies	Divided government may find some common ground on infrastructure spending, but policy paralysis more likely outcome	

Source: Credit Suisse research

Disclosure Appendix

Analyst Certification

Andrew Garthwaite, Robert Griffiths, Nicolas Wylenzek, Mengyuan Yuan, Asim Ali and Timothy O'Sullivan each certify, with respect to the companies or securities that the individual analyzes, that (1) the views expressed in this report accurately reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report.

As of December 10, 2012 Analysts' stock rating are defined as follows:

Outperform (O) : The stock's total return is expected to outperform the relevant benchmark* over the next 12 months.

Neutral (N) : The stock's total return is expected to be in line with the relevant benchmark* over the next 12 months.

Underperform (U) : The stock's total return is expected to underperform the relevant benchmark* over the next 12 months.

**Relevant benchmark by region: As of 10th December 2012, Japanese ratings are based on a stock's total return relative to the analyst's coverage universe which consists of all companies covered by the analyst within the relevant sector, with Outperforms representing the most attractive, Neutrals the less attractive, and Underperforms the least attractive investment opportunities. As of 2nd October 2012, U.S. and Canadian as well as European (excluding Turkey) ratings are based on a stock's total return relative to the analyst's coverage universe which consists of all companies covered by the analyst within the relevant sector, with Outperforms representing the most attractive, Neutrals the less attractive, and Underperforms the least attractive investment opportunities. For Latin America, Turkey and Asia (excluding Japan and Australia), stock ratings are based on a stock's total return relative to the average total return of the relevant country or regional benchmark (India - S&P BSE Sensex Index); prior to 2nd October 2012 U.S. and Canadian ratings were based on (1) a stock's absolute total return potential to its current share price and (2) the relative attractiveness of a stock's total return potential within an analyst's coverage universe. For Australian and New Zealand stocks, the expected total return (ETR) calculation includes 12-month rolling dividend yield. An Outperform rating is assigned where an ETR is greater than or equal to 7.5%; Underperform where an ETR less than or equal to 5%. A Neutral may be assigned where the ETR is between -5% and 15%. The overlapping rating range allows analysts to assign a rating that puts ETR in the context of associated risks. Prior to 18 May 2015, ETR ranges for Outperform and Underperform ratings did not overlap with Neutral thresholds between 15% and 7.5%, which was in operation from 7 July 2011.*

Restricted (R) : In certain circumstances, Credit Suisse policy and/or applicable law and regulations preclude certain types of communications, including an investment recommendation, during the course of Credit Suisse's engagement in an investment banking transaction and in certain other circumstances.

Not Rated (NR) : Credit Suisse Equity Research does not have an investment rating or view on the stock or any other securities related to the company at this time.

Not Covered (NC) : Credit Suisse Equity Research does not provide ongoing coverage of the company or offer an investment rating or investment view on the equity security of the company or related products.

Volatility Indicator [V] : A stock is defined as volatile if the stock price has moved up or down by 20% or more in a month in at least 8 of the past 24 months or the analyst expects significant volatility going forward.

Analysts' sector weightings are distinct from analysts' stock ratings and are based on the analyst's expectations for the fundamentals and/or valuation of the sector* relative to the group's historic fundamentals and/or valuation:

Overweight : The analyst's expectation for the sector's fundamentals and/or valuation is favorable over the next 12 months.

Market Weight : The analyst's expectation for the sector's fundamentals and/or valuation is neutral over the next 12 months.

Underweight : The analyst's expectation for the sector's fundamentals and/or valuation is cautious over the next 12 months.

**An analyst's coverage sector consists of all companies covered by the analyst within the relevant sector. An analyst may cover multiple sectors.*

Credit Suisse's distribution of stock ratings (and banking clients) is:

Global Ratings Distribution

Rating	Versus universe (%)	Of which banking clients (%)
Outperform/Buy*	50%	(33% banking clients)
Neutral/Hold*	37%	(28% banking clients)
Underperform/Sell*	11%	(20% banking clients)
Restricted	2%	

Please click [here](#) to view the MAR quarterly recommendations and investment services report for fundamental research recommendations.

**For purposes of the NYSE and FINRA ratings distribution disclosure requirements, our stock ratings of Outperform, Neutral, and Underperform most closely correspond to Buy, Hold, and Sell, respectively; however, the meanings are not the same, as our stock ratings are determined on a relative basis. (Please refer to definitions above.) An investor's decision to buy or sell a security should be based on investment objectives, current holdings, and other individual factors.*

Important Global Disclosures

Credit Suisse's research reports are made available to clients through our proprietary research portal on CS PLUS. Credit Suisse research products may also be made available through third-party vendors or alternate electronic means as a convenience. Certain research products are only made available through CS PLUS. The services provided by Credit Suisse's analysts to clients may depend on a specific client's preferences regarding the frequency and manner of receiving communications, the client's risk profile and investment, the size and scope of the overall client relationship with the Firm, as well as legal and regulatory constraints. To access all of Credit Suisse's research that you are entitled to receive in the most timely manner, please contact your sales representative or go to <https://plus.credit-suisse.com>.

Credit Suisse's policy is to update research reports as it deems appropriate, based on developments with the subject company, the sector or the market that may have a material impact on the research views or opinions stated herein.

Credit Suisse's policy is only to publish investment research that is impartial, independent, clear, fair and not misleading. For more detail please refer to Credit Suisse's Policies for Managing Conflicts of Interest in connection with Investment Research: <https://www.credit-suisse.com/sites/disclaimers-ib/en/managing-conflicts.html>.

Any information relating to the tax status of financial instruments discussed herein is not intended to provide tax advice or to be used by anyone to provide tax advice. Investors are urged to seek tax advice based on their particular circumstances from an independent tax professional.

Credit Suisse has decided not to enter into business relationships with companies that Credit Suisse has determined to be involved in the development, manufacture, or acquisition of anti-personnel mines and cluster munitions. For Credit Suisse's position on the issue, please see <https://www.credit-suisse.com/media/assets/corporate/docs/about-us/responsibility/banking/policy-summaries-en.pdf>.

The analyst(s) responsible for preparing this research report received compensation that is based upon various factors including Credit Suisse's total revenues, a portion of which are generated by Credit Suisse's investment banking activities

For date and time of production, dissemination and history of recommendation for the subject company(ies) featured in this report, disseminated within the past 12 months, please refer to the link: <https://rave.credit-suisse.com/disclosures/view/report?i=565060&v=-3q7q4ewd5a2ho6halo3wubpfk>.

Important Regional Disclosures

Singapore recipients should contact Credit Suisse AG, Singapore Branch for any matters arising from, or in connection with, this research report. The analyst(s) involved in the preparation of this report may participate in events hosted by the subject company, including site visits. Credit Suisse does not accept or permit analysts to accept payment or reimbursement for travel expenses associated with these events.

For Credit Suisse Securities (Canada), Inc.'s policies and procedures regarding the dissemination of equity research, please visit <https://www.credit-suisse.com/sites/disclaimers-ib/en/canada-research-policy.html>.

Investors should note that income from such securities and other financial instruments, if any, may fluctuate and that price or value of such securities and instruments may rise or fall and, in some cases, investors may lose their entire principal investment.

This research report is authored by:

Credit Suisse International Andrew Garthwaite ; Robert Griffiths ; Nicolas Wylenzek ; Mengyuan Yuan ; Asim Ali ; Timothy O'Sullivan

To the extent this is a report authored in whole or in part by a non-U.S. analyst and is made available in the U.S., the following are important disclosures regarding any non-U.S. analyst contributors: The non-U.S. research analysts listed below (if any) are not registered/qualified as research analysts with FINRA. The non-U.S. research analysts listed below may not be associated persons of CSSU and therefore may not be subject to the FINRA 2241 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Credit Suisse International Andrew Garthwaite ; Robert Griffiths ; Nicolas Wylenzek ; Mengyuan Yuan ; Asim Ali ; Timothy O'Sullivan

Important MSCI Disclosures

The MSCI sourced information is the exclusive property of Morgan Stanley Capital International Inc. (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, re-disseminated or used to create and financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI, Morgan Stanley Capital International and the MSCI indexes are services marks of MSCI and its affiliates.

The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of Morgan Stanley Capital International Inc. and Standard & Poor's. GICS is a service mark of MSCI and S&P and has been licensed for use by Credit Suisse.

Important Credit Suisse HOLT Disclosures

The HOLT methodology does not assign ratings or a target price to a security. It is an analytical tool that involves use of a set of proprietary quantitative algorithms and warranted value calculations, collectively called the HOLT valuation model, that are consistently applied to all the companies included in its database. Third-party data (including consensus earnings estimates) are systematically translated into a number of default variables and incorporated into the algorithms available in the HOLT valuation model. The source financial statement, pricing, and earnings data provided by outside data vendors are subject to quality control and may also be adjusted to more closely measure the underlying economics of firm performance. These adjustments provide consistency when analyzing a single company across time, or analyzing multiple companies across industries or national borders. The default scenario that is produced by the HOLT valuation model establishes a warranted price for a security, and as the third-party data are updated, the warranted price may also change. The default variables may also be adjusted to produce alternative warranted prices, any of which could occur. The warranted price is an algorithmic output applied systematically across all companies based on historical levels and volatility of returns. Additional information about the HOLT methodology is available on request.

CFROI, CFROE, HOLT, HOLT Lens, HOLTfolio, "Clarity is Confidence" and "Powered by HOLT" are trademarks or registered trademarks of Credit Suisse Group AG or its affiliates in the United States and other countries.

HOLT is a corporate performance and valuation advisory service of Credit Suisse.

© 2020 Credit Suisse Group AG and its subsidiaries and affiliates. All rights reserved.

Important disclosures regarding companies that are the subject of this report are available by calling +1 (877) 291-2683. The same important disclosures, with the exception of valuation methodology and risk discussions, are also available on Credit Suisse's disclosure website at <https://rave.credit-suisse.com/disclosures>. For valuation methodology and risks associated with any recommendation, price target, or rating referenced in this report, please refer to the disclosures section of the most recent report regarding the subject company.

This report is produced by subsidiaries and affiliates of Credit Suisse operating under its Global Markets Division. For more information on our structure, please use the following link: <https://www.credit-suisse.com/who-we-are>. This report may contain material that is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Credit Suisse or its affiliates ("CS") to any registration or licensing requirement within such jurisdiction. All material presented in this report, unless specifically indicated otherwise, is under copyright to CS. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of CS. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of CS or its affiliates. The information, tools and material presented in this report are provided to you for information purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or to buy or subscribe for securities or other financial instruments. CS may not have taken any steps to ensure that the securities referred to in this report are suitable for any particular investor. CS will not treat recipients of this report as its customers by virtue of their receiving this report. The investments and services contained or referred to in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about such investments or investment services. Nothing in this report constitutes investment, legal, accounting or tax advice, or a representation that any investment or strategy is suitable or appropriate to your individual circumstances, or otherwise constitutes a personal recommendation to you. Please note in particular that the bases and levels of taxation may change. Information and opinions presented in this report have been obtained or derived from sources believed by CS to be reliable, but CS makes no representation as to their accuracy or completeness. CS accepts no liability for loss arising from the use of the material presented in this report, except that this exclusion of liability does not apply to the extent that such liability arises under specific statutes or regulations applicable to CS. This report is not to be relied upon in substitution for the exercise of independent judgment. CS may have issued, and may in the future issue, other communications that are inconsistent with, and reach different conclusions from, the information presented in this report. Those communications reflect the different assumptions, views and analytical methods of the analysts who prepared them and CS is under no obligation to ensure that such other communications are brought to the attention of any recipient of this report. Some investments referred to in this report will be offered solely by a single entity and in the case of some investments solely by CS, or an associate of CS or CS may be the only market maker in such investments. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information, opinions and estimates contained in this report reflect a judgment at its original date of publication by CS and are subject to change without notice. The price, value of and income from any of the securities or financial instruments mentioned in this report can fall as well as rise. The value of securities and financial instruments is subject to exchange rate fluctuation that may have a positive or adverse effect on the price or income of such securities or financial instruments. Investors in securities such as ADRs, the values of which are influenced by currency volatility, effectively assume this risk. Structured securities are complex instruments, typically involve a high degree of risk and are intended for sale only to sophisticated investors who are capable of understanding and assuming the risks involved. The market value of any structured security may be affected by changes in economic, financial and political factors (including, but not limited to, spot and forward interest and exchange rates), time to maturity, market conditions and volatility, and the credit quality of any issuer or reference issuer. Any investor interested in purchasing a structured product should conduct their own investigation and analysis of the product and consult with their own professional advisers as to the risks involved in making such a purchase. Some investments discussed in this report may have a high level of volatility. High volatility investments may experience sudden and large falls in their value causing losses when that investment is realised. Those losses may equal your original investment. Indeed, in the case of some investments the potential losses may exceed the amount of initial investment and, in such circumstances, you may be required to pay more money to support those losses. Income yields from investments may fluctuate and, in consequence, initial capital paid to make the investment may be used as part of that income yield. Some investments may not be readily realisable and it may be difficult to sell or realise those investments, similarly it may prove difficult for you to obtain reliable information about the value, or risks, to which such an investment is exposed. This report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to website material of CS, CS has not reviewed any such site and takes no responsibility for the content contained therein. Such address or hyperlink (including addresses or hyperlinks to CS's own website material) is provided solely for your convenience and information and the content of any such website does not in any way form part of this document. Accessing such website or following such link through this report or CS's website shall be at your own risk.

This report is issued and distributed in **European Union (except Germany and Spain)**: by Credit Suisse Securities (Europe) Limited, One Cabot Square, London E14 4QJ, England, which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority; **Spain**: Credit Suisse Securities, Sociedad de Valores, S.A. ("CSSSV") regulated by the Comisión Nacional del Mercado de Valores; **Germany**: Credit Suisse (Deutschland) Aktiengesellschaft regulated by the Bundesanstalt für Finanzdienstleistungsaufsicht ("BaFin"); **United States**: Credit Suisse Securities (USA) LLC; **Canada**: Credit Suisse Securities (Canada), Inc.; **Switzerland**: Credit Suisse AG; **Brazil**: Banco de Investimentos Credit Suisse (Brasil) S.A. or its affiliates; **Mexico**: Banco Credit Suisse (México), S.A., Institución de Banca Múltiple, Grupo Financiero Credit Suisse (México) and Casa de Bolsa Credit Suisse (México), S.A. de C.V., Grupo Financiero Credit Suisse (México) ("Credit Suisse Mexico"); This document has been prepared for information purposes only and is exclusively distributed in Mexico to Institutional Investors. Credit Suisse Mexico is not responsible for any onward distribution of this report to non-institutional investors by any third party. The authors of this report have not received payment or compensation from any entity or company other than from the relevant Credit Suisse Group company employing them; **Japan**: by Credit Suisse Securities (Japan) Limited, Financial Instruments Firm, Director-General of Kanto Local Finance Bureau (Kinsiro) No. 66, a member of Japan Securities Dealers Association, The Financial Futures Association of Japan, Japan Investment Advisers Association, Type II Financial Instruments Firms Association; **Hong Kong**: Credit Suisse (Hong Kong) Limited; **Australia**: Credit Suisse Equities (Australia) Limited; **Thailand**: Credit Suisse Securities (Thailand) Limited, regulated by the Office of the Securities and Exchange Commission, Thailand, having registered address at 990 Abdulrahim Place, 27th Floor, Unit 2701, Rama IV Road, Siom, Bangkok, Bangkok10500, Thailand, Tel. +66 2614 6000; **Malaysia**: Credit Suisse Securities (Malaysia) Sdn Bhd; **Singapore**: Credit Suisse AG, Singapore Branch; **India**: Credit Suisse Securities (India) Private Limited (CIN no.U67120MH1996PTC104392) regulated by the Securities and Exchange Board of India as Research Analyst (registration no. INH 000001030) and as Stock Broker (registration no. INZ000248233), having registered address at 9th Floor, Ceejay House, Dr.A.B. Road, Worli, Mumbai - 18, India, T- +91-22 6777 3777; **South Korea**: Credit Suisse Securities (Europe) Limited, Seoul Branch; **Taiwan**: Credit Suisse AG Taipei Securities Branch; **Indonesia**: PT Credit Suisse Sekuritas Indonesia; **Philippines**: Credit Suisse Securities (Philippines) Inc., and elsewhere in the world by the relevant authorised affiliate of the above.

Additional Regional Disclaimers

Australia: Credit Suisse Securities (Europe) Limited ("CSSEL") and Credit Suisse International ("CSI") are authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority ("FCA") and the Prudential Regulation Authority under UK laws, which differ from Australian laws. CSSEL and CSI do not hold an Australian Financial Services Licence ("AFSL") and are exempt from the requirement to hold an AFSL under the Corporations Act (Cth) 2001 ("Corporations Act") in respect of the financial services provided to Australian wholesale clients (within the meaning of section 761G of the Corporations Act) (hereinafter referred to as "Financial Services"). This material is not for distribution to retail clients and is directed exclusively at Credit Suisse's professional clients and eligible counterparties as defined by the FCA, and wholesale clients as defined under section 761G of the Corporations Act. Credit Suisse (Hong Kong) Limited ("CSHK") is licensed and regulated by the Securities and Futures Commission of Hong Kong under the laws of Hong Kong, which differ from Australian laws. CSHK does not hold an AFSL and is exempt from the requirement to hold an AFSL under the Corporations Act in respect of providing Financial Services. Investment banking services in the United States are provided by Credit Suisse Securities (USA) LLC, an affiliate of Credit Suisse Group. CSSU is regulated by the United States Securities and Exchange Commission under United States laws, which differ from Australian laws. CSSU does not hold an AFSL and is exempt from the requirement to hold an AFSL under the Corporations Act in respect of providing Financial Services. Credit Suisse Asset Management LLC (CSAM) is authorised by the Securities and Exchange Commission under US laws, which differ from Australian laws. CSAM does not hold an AFSL and is exempt from the requirement to hold an AFSL under the Corporations Act in respect of providing Financial Services. This material is provided solely to Institutional Accounts (as defined in the FINRA rules) who are Eligible Contract Participants (as defined in the US Commodity Exchange Act). Credit Suisse Equities (Australia) Limited (ABN 35 068 232 708) ("CSEAL") is an AFSL holder in Australia (AFSL 237237).

Malaysia: Research provided to residents of Malaysia is authorised by the Head of Research for Credit Suisse Securities (Malaysia) Sdn Bhd, to whom they should direct any queries on +603 2723 2020.

Singapore: This report has been prepared and issued for distribution in Singapore to institutional investors, accredited investors and expert investors (each as defined under the Financial Advisers Regulations) only, and is also distributed by Credit Suisse AG, Singapore Branch to overseas investors (as defined under the Financial Advisers Regulations). Credit Suisse AG, Singapore Branch may distribute reports produced by its foreign entities or affiliates pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Singapore recipients should contact Credit Suisse AG, Singapore Branch at +65-6212-2000 for matters arising from, or in connection with, this report. By virtue of your status as an institutional investor, accredited investor, expert investor or overseas investor, Credit Suisse AG, Singapore Branch is exempted from complying with certain compliance requirements under the Financial Advisers Act, Chapter 110 of Singapore (the "FAA"), the Financial Advisers Regulations and the relevant Notices and Guidelines issued thereunder, in respect of any financial advisory service which Credit Suisse AG, Singapore Branch may provide to you.

EU: This report has been produced by subsidiaries and affiliates of Credit Suisse operating under its Global Markets Division

In jurisdictions where CS is not already registered or licensed to trade in securities, transactions will only be effected in accordance with applicable securities legislation, which will vary from jurisdiction to jurisdiction and may require that the trade be made in accordance with applicable exemptions from registration or licensing requirements.

This material is issued and distributed in the U.S. by CSSU, a member of NYSE, FINRA, SIPC and the NFA, and CSSU accepts responsibility for its contents. Clients should contact analysts and execute transactions through a Credit Suisse subsidiary or affiliate in their home jurisdiction unless governing law permits otherwise.

CS may provide various services to US municipal entities or obligated persons ("municipalities"), including suggesting individual transactions or trades and entering into such transactions. Any services CS provides to municipalities are not viewed as "advice" within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act. CS is providing any such services and related information solely on an arm's length basis and not as an advisor or fiduciary to the municipality. In connection with the provision of the any such services, there is no agreement, direct or indirect, between any municipality (including the officials, management, employees or agents thereof) and CS for CS to provide advice to the municipality. Municipalities should consult with their financial, accounting and legal advisors regarding any such services provided by CS. In addition, CS is not acting for direct or indirect compensation to solicit the municipality on behalf of an unaffiliated broker, dealer, municipal securities dealer, municipal advisor, or investment adviser for the purpose of obtaining or retaining an engagement by the municipality for or in connection with Municipal Financial Products, the issuance of municipal securities, or of an investment adviser to provide investment advisory services to or on behalf of the municipality. If this report is being distributed by a financial institution other than Credit Suisse AG, or its affiliates, that financial institution is solely responsible for distribution. Clients of that institution should contact that institution to effect a transaction in the securities mentioned in this report or require further information. This report does not constitute investment advice by Credit Suisse to the clients of the distributing financial institution, and neither Credit Suisse AG, its affiliates, and their respective officers, directors and employees accept any liability whatsoever for any direct or consequential loss arising from their use of this report or its content. No information or communication provided herein or otherwise is intended to be, or should be construed as, a recommendation within the meaning of the US Department of Labor's final regulation defining "investment advice" for purposes of the Employee Retirement Income Security Act of 1974, as amended and Section 4975 of the Internal Revenue Code of 1986, as amended, and the information provided herein is intended to be general information, and should not be construed as, providing investment advice (impartial or otherwise).

Copyright © 2020 CREDIT SUISSE AG and/or its affiliates. All rights reserved.

When you purchase non-listed Japanese fixed income securities (Japanese government bonds, Japanese municipal bonds, Japanese government guaranteed bonds, Japanese corporate bonds) from CS as a seller, you will be requested to pay the purchase price only.